💡 The fall of the pharmaceutical company!💉
Shares of Moderna $MRNA were rocked today as their value fell by more than 20 % after the company cut its 2025 revenue estimate by $1 billion. The event raised questions among investors about where the company is headed. 📉💼

Moderna now expects its revenue in the year 2025 will be 1.5-2.5 billion dollars by 2025, with most of that revenue expected in the second half of the year. However, this new estimate is noticeably lower than previous expectations, which were in the range of 2.5-3.5 billion.

The biotech giant faces several challenges:
Declining demand for Covid-19vaccines - The initial boom has faded, vaccination rates are down, and so are revenues.
Increasing competition - Sanofi $SAN.PA, Novavax $NVAX and others are strengthening their positions in the vaccine market.
Decliningmarket share - Moderna has lost some of its U.S. market share, which has fallen from 48 % in 2023 to 40 % in 2024.

Uncertainty around new vaccines - Recommendations from health authorities such as the CDC regarding RSV vaccination are still uncertain, which is affecting planning.

Despite these challenges, the company believes it has a solid foundation for the future. 🧬

Portfolio diversification: Moderna plans to launch up to 10 new products over the next three years , including combination vaccines (Covid + flu) and new generations of mRNA-based injections.
Cost Reduction: the company plans to reduce costs by $1 billion in 2025and another $500 million in 2026. The move should boost cash flow and the company's stability.
Growthbeyond Covid: TheRSVvaccine , which only recently entered the market, is expected to be a key part of the new strategy. The company also plans to expand into other areas such as oncology and next-generation flu vaccines.

Key figures and facts:
Revenues 2024: The company achieved revenues of around $3 billion, meeting its estimates. By comparison, Covid vaccine revenues were $18 billion in 2022, indicating a sharp decline.
Profit outlook: the company plans to break even in 2028, up from its original 2026 plan .

Moderna remains an interesting but risky investment. While the short-term outlook is not optimistic, its long-term strategy relies on innovation and expanding its portfolio beyond Covid.

Do you have Moderna in your portfolio? How do you see its future - is it still an opportunity or time to consider an exit?